The results show that trifluridine/tipiracil is more clinically and cost-effective than regorafenib, with clinical outcomes greatly exceeding those for patients treated with BSC alone. Based on the results of the analysis, trifluridine/tipiracil offers an important new treatment option for patients with mCRC maintaining good performance status at the end of life.
were women. The control group was selected to show an optimal comparability in terms of demographic and morbidity measures between the two groups. The intervention group showed better compliance (87.9% vs. 71.4%, p= 0.001). BP control was 52.5 vs. 53.1% (p= NS) initially and 63.2% vs. 55.6% at the end of the study (p< 0.001) for the intervention group vs. control, respectively. The follow-up average cost per patient and year was € 377.9 vs. € 442.4, p< 0.001 (reduction in intervention group: 66 € ). 82% of health care professionals and 91% of patients were satisfied with the DMP. ConClusions: The DMP has improved adherence to treatment and BP control and has reduced health care management costs. If the study results were extrapolated to the overall population of Badalona, a potential saving of 1.7 million per year would be achieved.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.